Cite
HARVARD Citation
Pusceddu, S. et al. (2014). Rationale and protocol of the MetNET-1 trial, a prospective, single center, phase II study to evaluate the activity and safety of everolimus in combination with octreotide LAR and metformin in patients with advanced pancreatic neuroendocrine tumors. Tumori. 100 (6), pp. e286-e289. [Online].